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E-mail address: richard.roy@mcgill.ca (R. Roy).AMPK is a protein kinase activated by various cellular stresses such as glucose deprivation, hypoxia
or exercise. Despite having been studied for decades only a limited number of targets have been well
described in tissues as varied as liver, muscle, and adipose tissue. Recent studies have shown that
AMPK does not function in a similar manner, or through identical targets, in all cellular situations,
posing challenges to some accepted paradigms describing AMPK function. A combination of genetic
models and cell biological analysis of AMPK function in speciﬁc cell/developmental/environmental
contexts will be required to accurately complement our understanding of the role(s) of AMPK in
cancer, diabetes and other diseases.
Crown Copyright  2010 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.The effects of glucose deprivation, hypoxia and numerous other
cellular stresses trigger the activation of the AMP-activated protein
kinase (AMPK), prompting it to appropriately re-distribute re-
sources to provide the cell with the required energy for survival.
To do this, AMPK will alter cellular metabolism by blocking ATP-
consuming pathways, while activating those that generate ATP.
These include a marked increase in glucose uptake, a stimulation
of fatty acid oxidation, and an inhibition of glycogen, fatty acid,
cholesterol, and protein synthesis. The action of AMPK can be acute
due to a direct phosphorylation of target proteins, such as various
metabolic enzymes, or it can be more long-term through its ability
to phosphorylate critical transcription factors that regulate the
expression of metabolically-responsive target genes. Although
AMPK has long been described as a master metabolic regulator,
the identiﬁcation of the key kinase substrates required to adjust
its characteristic metabolic outputs downstream of cellular energy
stress has been limited to 20 targets, most of which cannot solely
account for the major cellular changes that occur upon activation
of this stress pathway. Furthermore, the spectrum of targets and
the effects of AMPK activation downstream of nutrient stress ap-
pear to vary between cell types and developmental contexts, mak-
ing it increasingly difﬁcult to make large general conclusions about
the various AMPK-dependent outputs. We highlight a few of these
situations here, emphasizing the importance of re-evaluating many
of the current paradigms dictating our understanding of howd by Elsevier B.V. on behalf of FedeAMPK may affect the speciﬁc cellular changes that occur in re-
sponse to reduced cellular energy levels.
These events occur in most tissues, but are best understood in
the liver, muscle, heart and adipose tissue where AMPK may have
cell/tissue/developmental context-speciﬁc consequences. This is
perhaps best reﬂected in the regulation of lipid metabolism down-
stream of AMPK activation. In many organisms, the response to re-
duced cellular energy stores impinges on AMPK which will
attenuate lipogenesis in organs such as muscle and liver, in part
through the phosphorylation of two well-characterized targets:
Acetyl-CoA Carboxylases 1 and 2 (ACC1 and ACC2). These enzymes
catalyze the synthesis of malonyl-CoA, a pivotal substrate for fatty
acid synthesis and the regulator of fatty acid oxidation. The func-
tional distinction between ACC1 and ACC2 lies in their subcellular
distribution; ACC1 is cytoplasmic whereas ACC2 is associated with
mitochondria. The inhibitory effects on fatty acid synthesis down-
stream of AMPK activation are likely mediated by the AMPK-
dependent phosphorylation and subsequent inhibition of ACC1.
On the other hand, the AMPK-mediated stimulation of fatty acid
oxidation is achieved by direct phosphorylation and inhibition of
ACC2 [1]. Both of these events result in a general reduction of lipid
stores and consequent ATP production in response to energy stress.
Although this scenario is well accepted and likely highly con-
served among many organisms, AMPK does not always affect lipid
metabolism in this generalized manner. In the nematode
Caenorhabditis elegans, larvae subjected to inadequate growing
conditions opt to execute an alternative developmental stage re-
ferred to as dauer, where animals stop foraging and prepare, bothration of European Biochemical society. All rights reserved.
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tremes. This developmental switch is controlled in part by insulin
signaling and at least two other highly conserved signaling path-
ways and is associated with major changes in metabolism, cell
division and behaviour.
Upon executing the dauer program, larvae accumulate lipid as a
long-term energy resource, while implementing a general state of
developmental quiescence. Some of these changes are AMPK-
dependent, and in its absence many of these controls go awry. Par-
ticularly noteworthy, the germline stem cells of the AMPK mutant
dauer larvae exit quiescence and begin to hyperproliferate giving
rise to a marked hyperplasia [2]. In addition, the increased lipid
stores typical of the dauer larvae become rapidly exhausted, which
eventually leads to premature lethality in these mutant dauer ani-
mals. Although both events occur through independent down-
stream effectors, both are under the control of the upstream
regulators of AMPK, namely LKB1 and STRADa. The literature is
rich in references that link AMPK activity to hormone sensitive li-
pase (HSL), particularly in muscle cells during intense bouts of
exercise-associated energy stress [3]. It would therefore seem intu-
itive that a similar interaction between HSL and AMPK would be
responsible for the observed response in lipid hydrolysis at the on-
set of dauer. Curiously, in AMPK mutant dauer larvae, the loss of
HSL has no effect on the accelerated lipid hydrolysis. Alternatively,
AMPK was demonstrated to act through the phospho-inhibition of
a triglyceride lipase called ATGL-1 to block lipid hydrolysis during
this developmentally quiescent stage [4]. In wild type dauer larvae
the AMPK-dependent inhibition of ATGL-1 activity allows the lipid
stores to accumulate and persist, presumably to provide a thresh-
old level of energy over the course of the diapause for the nutrient-
challenged dauer larva. It is not clear how AMPK affects other en-
zymes normally involved in lipogenesis during this transition
(Fig. 1). However, the accumulation of lipid in AMPK mutant dau-
ers seems quite similar to wild type animals suggesting that lipo-
genesis is not adversely affected by its absence. The parallels of
dauer with other organisms are quite compelling and similar
mechanisms may be at play in animals that undergo extended
periods of inactivity or hibernation.
One of the major metabolic pathways that drive cellular ATP
production is glycolysis and, not surprisingly, AMPK activity can
inﬂuence glycolytic ﬂux, although its function in this regard re-
mains controversial. In skeletal muscle, one of the principal roles
of AMPK is to stimulate glucose uptake via the translocation of
the glucose transporter GLUT4 to the plasma membrane. Phos-
phorylation of the Rab-GAP protein TBC1D4 is regulated by AMPKFig. 1. Opposite effects of AMPK on lipid storage and hydrolysis. The regulation of
lipid turnover that occurs following the activation of AMPK/AAK-2 cannot be
generalized and is highly dependent on both the cellular and developmental
context. In mammalian cells in culture, activated AMPK blocks lipogenesis by
phosphorylating key mitochondrial enzymes involved in lipogenesis. In contrast,
during the C. elegans dauer stage, the activity of a critical triglyceride lipase (ATGL-
1) is phospho-inhibited by AAK-2, one of the two catalytic subunits of AMPK in C.
elegans, allowing the larva to utilize the stored lipids as a long-term energy
resource.in skeletal muscle [5], while the closely related paralog TBC1D1 has
also been shown to be phosphorylated by AMPK in response to
insulin and contraction [6,7]. The GLUT1 transporter can also be
activated by AMPK, although the critical kinase target involved
remains yet to be identiﬁed [8]. AMPK has been shown to stimulate
glycolysis in heart through phosphorylation of PFK2 at Ser-466 [9].
The biguanide metformin, which acts as an indirect activator of
AMPK, can also stimulate glycolysis in cells in an AMPK-dependent
manner [10]. However, AMPK activity does not always correlate
with increased glycolysis. AICAR, an AMPK agonist, can actually in-
hibit glycolysis in multiple cell types in an AMPK-dependent fash-
ion [11–13]. It is possible that the effect of AMPK on glycolysis may
depend on either tissue type or the context in which AMPK is acti-
vated. Future work using tissue-speciﬁc deletions of AMPK should
help to clarify the controversy surrounding the role of AMPK in this
critical process.
Many of the characteristic AMPK-dependent changes that occur
in muscle are not due to direct phosphorylation of enzymatic sub-
strates, but rather due to chronic changes in the muscle-speciﬁc
transcriptional repertoire downstream of AMPK activation. This is
achieved through the phosphorylation of different transcription
factors expressed in the muscle, such as the transcriptional co-
activator Peroxisome proliferator-activated receptor Gamma Coac-
tivator 1-alpha (PGC-1a), the transcription factor GLUT4 Enhancer
Factor (GEF), and/or the derepression of the transcription factor
Myocyte Enhancer Factor-2 (MEF2) via phosphorylation of Histone
Deacetylase 5 (HDAC5) [14]. Each of these transcriptional changes
will favor GLUT4 transcription and its subsequent expression and
translocation to its site of function at the plasma membrane. These
effects occur quite rapidly after a bout of exercise resulting in a
concomitant increase in the rate of glucose uptake. Thus, AMPK
will control multiple aspects of myocyte homeostasis following
exercise and muscle contraction to allow the skeletal muscle to
adapt to this speciﬁc physiologic state.
In the liver, one of best-documented effects of AMPK is its sup-
pression of hepatic gluconeogenesis through the action of a num-
ber of transcription factors that include CREB Binding Protein
(CBP) [15], its co-activator CRTC2 [16], and the orphan nuclear
receptor SHP [17]. SHP has been shown to be an important contrib-
utor of AMPK-dependent suppression of CREB/CRTC2-mediated
hepatic gluconeogenic gene expression [18]. These modiﬁcations
will, inter alia, down-regulate the expression of gluconeogenic
genes such as Phosphoenolpyruvate Carboxykinase (PEPCK) and
Glucose-6-Phosphatase (G6Pase) [19]. These enzymes regulate
two important reactions of gluconeogenesis: the synthesis of PEP
from oxaloacetate and that of glucose from glucose-6-phosphate
(G6P). Therefore, by blocking the activity of these critical transcrip-
tion factors, AMPK can decrease the rate of gluconeogenic ﬂux.
The typical acute/chronic duality of the AMPK response is yet
further reﬂected in its ability to reduce the expression of genes that
regulate lipogenesis. In addition to its acute effects on ACC1/2,
AMPK phosphorylates and thereby inhibits the Carbohydrate-
Responsive Element-Binding Protein (ChREBP) by decreasing its
DNA binding activity [20], whereby it affects the expression of
ACC1 and Fatty acid Synthase [21]. Moreover, activation of AMPK
also inhibits the Sterol Regulatory Element Binding Protein-1
(SREBP1-c) [22], which is required for the appropriate expression
of ACC1 [23].
Therefore, in response to metabolic imbalance, AMPK initiates
both short term and long-term effects to right bioenergetic homeo-
stasis. The ‘‘ﬁrst wave’’ response by AMPK is mediated through
post-translational modiﬁcations which can acutely affect the activ-
ity of key metabolic enzymes/effectors (i.e. eEF2, PFK2 or mTORC1),
while in the long term, activated AMPK can alter gene output by
phosphorylating transcription factors, transcriptional cofactors,
chromatin modifying enzymes including histone deacetylases
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matin conﬁguration [25], thereby modulating target gene expres-
sion in response to cellular energy stress.
Sirtuins are highly conserved NAD+-dependent histone/protein
deacetylases. These enzymes have been shown to regulate diverse
cellular processes that range from inﬂammation, metabolism,
cellular senescence/aging to cellular apoptosis/proliferation, differ-
entiation, stem cell pluripotency, and cell proliferation [26]. The
best-known and most studied member of this family is the Silent
Information Regulator T1 (SIRT1). SIRT1 is able to deacetylate ly-
sine residues in a reaction that consumes NAD+, and releases nico-
tinamide, O-acetyl ADP ribose (AADPR), and the deacetylated
product [26]. For this reason, the activity of SIRT1 is highly depen-
dent on the intracellular levels of NAD+. The generation of NAD+ in
the cell can occur de novo via the use of tryptophan, or alterna-
tively through the more energy efﬁcient Salvage Pathway. The en-
zymes required for NAD+ salvage include NAMPT (nicotinamide
phosphoribosyltransferase) and NMNAT (nicotinamide mononu-
cleotide adenylyltransferase) and are thus critical for the regula-
tion of SIRT1. SIRT1 responds to numerous cellular stresses such
as fasting, exercise, or low glucose availability, all of which are also
associated with increases in the cellular levels of NAD+ [28]. AMPK
activity has been shown to increase cellular NAD+ levels [28],
although whether this occurs through regulation of the NAD+ sal-
vage pathway remains unclear The characteristic lifespan exten-
sion that occurs in yeast, Drosophila melanogaster and C. elegans
following caloric restriction or conditions of nutrient stress are also
associated with SIRT1 activity [27,29] and it is likely that SIRT1 can
regulate these processes through its ability to deacetylate histone
or non-histone proteins [30]. SIRT1 and AMPK have many common
actions on various processes such as metabolism and mitochon-
drial function and recently, the link between these two sensor pro-
teins has become more obvious.
Using heterozygous SIRT mice under conditions of glucose
restriction (GR), it was shown that AMPK, NAMPT and SIRT1 are
part of the same pathway that allows skeletal muscle cells to sense
and react to nutrient availability [31]. GR activates AMPK which in-
duces NAMPT transcription in a SIRT1 dependent manner, conse-
quently augmenting the cellular NAD+:NADH ratio.
The mechanism through which AMPK enhances SIRT1 activity
appears to rely on increases in cellular NAD+ levels, although this
seems to be at odds with the function of AMPK in fatty acid oxida-
tion, which should result in increased cellular levels of NADH. How
the cell perceives these changes and executes the appropriate
downstream events remains yet to be elucidated. Nevertheless,
the NAD+-dependent activation of SIRT1 is responsible for the
deacetylation of targets that include PGC-1a, FOXO1 and FOXO3a
[28]. Similarly, AMPK is necessary to act as the primary sensor in
C2C12 myotubes during fasting and exercise to activate SIRT1
and its downstream targets [32]. Therefore, taken altogether these
recent data indicate that both AMPK and SIRT1 cooperate in a com-
mon pathway through their independent roles in regulating lipid
metabolism and mitochondrial biogenesis and that many of the
observed metabolic effects of SIRT1 may be, in fact, responses to
cellular changes mediated by AMPK function.
Although the recent link made between AMPK and SIRT1 clari-
ﬁes a number of relatedmetabolic phenomena associatedwith each
of these gene products, it has been well established that AMPK acti-
vation exerts a substantial impact on many of the regulatory com-
ponents involved in mitochondrial biogenesis and/or function.
Long-term exercise training increases oxidative capacity in
muscle through its positive effects on mitochondrial biogenesis
resulting mainly from the metabolic and nutrient stress that occurs
within cells. Various studies have shown that AMPK is required for
the increased numbers of mitochondria observed in skeletal mus-
cle in response to energy deprivation in [33,34]. However, theunderstanding of the AMPK-dependent mechanism that regulates
these mitochondrial processes has been signiﬁcantly enhanced
through identiﬁcation and characterization of key AMPK targets in-
volved in mitochondrial biogenesis. The over-expression of a mu-
tant variant of the AMPKc3 subunit increases mitochondrial
biogenesis in glycolytic skeletal muscle. This is correlated with a
signiﬁcant increase in the expression of PGC-1a and several tran-
scription factors that regulate mitochondrial biogenesis including
Nuclear Respiratory Factor 1 (NRF-1), NRF-2 and Transcription Fac-
tor A, Mitochondrial (TFAM) [35].
PGC-1a is a master regulator of oxidative metabolism and is
able to cooperate with a number of transcription factors that con-
trol metabolic and mitochondrial gene expression, including the
Peroxisome Proliferator-Activated Receptors (PPARs), the thyroid
hormone receptor, glucocorticoid receptor, estrogen receptor,
MEF-2 and FOXO transcription factors [36]. In general, through
its coactivator function, PGC-1a will increase mitochondrial activ-
ity during conditions of energy deﬁciency, and alternatively atten-
uate it when the energy requirement is low. Moreover, in addition
to its effects on NAD+-dependent SIRT1 activation, AMPK can also
activate PGC-1a through a direct interaction and resulting phos-
phorylation in skeletal muscle [37]. Not surprisingly the transcrip-
tional expression proﬁle that is affected by PGC-1a corresponds
quite closely to the spectrum of gene activities that also fall under
AMPK control, suggesting that PGC-1a is the major effector regu-
lating mitochondrial biogenesis downstream of AMPK activation.
Recently, a number of drugs that modify mitochondrial function
have been developed for use in the clinic (Table 1). Metformin is
the widespread drug of choice for treating type II diabetes world-
wide and recent estimates predict that 42 million patients are
being prescribed the drug in the USA alone. Its efﬁciency in lower-
ing blood glucose and controlling insulin levels in diabetic patients
is unquestionable, although until recently its mechanism of action
has eluded investigators.
Metformin is thought to be a weak mitochondrial poison that
targets complex one of the electron transport chain (ETC) in mito-
chondria. The ETC is the major site of oxidative phosphorylation
where it uses the energy released through the oxidation of nutri-
ents to produce ATP. The ETC is composed of 5 complexes that con-
vert the energy released following the transfer of electrons to
produce a proton gradient across the mitochondrial inner mem-
brane. This electrochemical proton gradient is then used by ATP
synthase to generate ATP from ADP and Pi. It is through this effect
that metformin is capable of modifying the cellular energy charge,
which was assumed to be countered by the induction of AMPK and
thereby mediate the beneﬁcial effects of the drug [22].
However, several recent studies have challenged this idea. It has
proven quite difﬁcult to demonstrate any signiﬁcant increase of
the AMP:ATP ratio in isolated cells (muscle, Chinese hamster ovary
ﬁbroblasts or the rat hepatoma cell line H4IIE) following treatment
with metformin [38,39]. However, this may be a technical hurdle
that reﬂects the ability (or inability) to accurately measure active
or free adenine nucleotide levels as opposed to total; which com-
prises mostly protein-bound/sequestered nucleotides, in various
cell types, since in studies conducted with intact hepatocytes, the
ADP:ATP ratio in both the cytosolic and the mitochondrial com-
partments increased after metformin administration [40]. Simi-
larly, metformin-induced increases in the AMP:ATP ratio have
been recently shown in primary hepatocytes and the liver of mice
[41], while after a perfusion of metformin in intact rat heart, an in-
crease of AMPK activity correlated with a increase in cytoplasmic
AMP [42]. It is noteworthy that in this study both the total AMP
content and the total AMP:ATP ratio did not change. Therefore, it
is difﬁcult to conclude whether indeed metformin alters the cellu-
lar AMP:ATP ratio as it may depend on the cellular context or, more
likely, the sensitivity of the quantitative methods employed.
Table 1
Drugs used to detect modiﬁcation of AMP:ATP and/or ADP:ATP ratio in different contexts. For each drug, the model and the maximal concentration used is indicated, together
with the variation observed for the ratios.
Drug Ratio AMP:ATP Ratio ADP:ATP Model Maximal concentrations used References
Biguanides Metformin = H-2Kb cells (skeletal muscle, mouse)
Heart (rat)
2 mM
10 mM
[36,40]
= CHO and H4IIE cells (hepatoma, rat)
HEK 293 cells (kidney, human)
5 mM
3mM
[37,41]
" Primary hepatocytes (mice)
Liver (mice)
2 mM
20 mg/kg
[39]
" Liver (rats) 2 mM [50]
Phenformin " Brain slices (rat) 5 mM [51]
" HEK 293 cells 3 mM [41]
Galegine " HEK 293 cells 0.1 mM [41]
A-769662 = Primary hepatocytes (rat)
HEK 293 cells
0.1 mM
0.3 mM
[41,52,53]
PT1 = L6 myotubes (rat) 0.08 mM [54]
Thiazolidinediones Rosiglitazone " H-2Kb cells 0.2 mM [36]
Troglitazone " HEK 293 cells 0.1 mM [41]
Pioglitazone " Liver (rat) 3 mg/kg [55]
Barbiturate Phenobarbital " HEK 293 cells 3 mM [41]
Phytochemicals Berberine " HEK 293 cells 0.1 mM [41]
" " L6 myotubes 0.02 mM [56]
Quercetin " HEK 293 cells 0.3 mM [41]
Resveratrol " HEK 293 cells 0.3 mM [41]
AICAR " Hepatocytes (rat) 0.1 mM [57]
= HEK 293 cells 3 mM [41]
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AMPK variant through the overexpression of mutant forms of the
AMPKc subunit has provided additional clues that have helped to
discriminate between these different observations [43]. A plethora
of compounds were used to test the response of wild type or mu-
tant expressing cells and, although many of these compounds af-
fect the ADP:ATP ratio signiﬁcantly, metformin did not. The
authors do indicate that metformin was indeed capable of activat-
ing AMPK, presumably by increasing cellular AMP concentrations.
Again, this may stem from the inability to accurately quantify very
low AMP levels as this ratio varies as the square of the ADP:ATP ra-
tio [44]. It seems that the change in the AMP:ATP ratio, or perhaps
more accurately, the lack thereof, cannot be used as an accurate
measure of AMPK activation. The degree of change and/or the crit-
ical threshold of AMP that might cause AMPK activation may once
more be dependent on the cell type and culture conditions. Since
the effects of metformin on hepatic glucose production have been
well documented and work in parallel to its inhibitory effects on
gluconeogenesis [45], studies conducted in vivo on liver, or at least
on isolated hepatocytes, may ultimately be the most informative
means of investigating the cellular action of metformin. These data
demonstrate that assuming a link between the change of the
AMP:ATP ratio and the activation of AMPK may not always be cor-
rect, and that the change in cellular energy stores, and the activity
of the kinase may, to some degree, be two phenomena that act in
parallel, but not necessarily be directly related.
In a wave of studies that appeared earlier this year, the impor-
tance of AMPK in exerting the positive, health-beneﬁcial effects of
metformin has been challenged. It has been generally assumed that
AMPK activation by metformin ultimately leads to the inhibition of
mTORC1 [46] in a TSC1/2-dependent manner [47], or alternatively
through phosphorylation of Raptor [48]. However, recent
experiments performed using mouse embryonic ﬁbroblasts from
gene targeted animals demonstrated that the characteristic inhibi-
tion of mTORC1 by biguanide-derived drugs (metformin and
phenformin) can occur in a manner independent of TSC1/2, and
more surprisingly and unexpectedly, independent of AMPK. This
surprising ﬁnding suggests that biguanides may use alternativetargets to confer their beneﬁcial metabolic/growth effects in cells
by blocking TOR kinase activity, potentially through their inhibi-
tory effects on Rag GTPases, although the effect of a true genetic
Rag GTPase loss of function on the downstream effects of the
biguanide drugs has not been rigorously investigated [49].
In a very important and inﬂuential study, LKB1 was shown to
mediate the inhibitory effects of metformin on gluconeogenesis
in the mouse liver [50]. However a recent genetic study using
hepatocytes lacking functional AMPK or LKB1 showed that neither
AMPK, nor LKB1 is essential for metformin-mediated inhibition of
hepatic glucose production [41]. Moreover, although it is accepted
that AMPK inhibits the expression of the G6Pase in rat hepatoma
cells, the inhibition of G6Pase by metformin is independent of
complex I and of AMPK activation [51]. Since gluconeogenesis is
highly energy-consuming it is probable that the reduced mito-
chondrial output conferred by metformin treatment could directly
impact the process and shunt any requirement for either of LKB1 or
AMPK. These recent ﬁndings prompt a re-evaluation of the current,
accepted paradigm of AMPK function as an obligate downstream
effector of metformin action.
The last decade has seen extraordinary advances in our under-
standing of how diabetes, obesity, and cancer are linked to a com-
plex cascade of protein kinase activity that impinge on AMPK,
resulting in both acute and chronic effects on cellular metabolism
through phosphorylation of key protein substrates. The upcoming
decade will hopefully allow us to further identify and characterize
these critical targets to design novel strategies around their control
to ameliorate these three disorders, and perhaps many others. The
examples that we have highlighted in this review underscore the
importance of the use of multiple cell and animal models, since
the generalized paradigms describing AMPK function have not pro-
ven robust over time when rigorously challenged. The recent new
developments described in this review emphasize the critical role
of genetic analysis in permitting non-biased approaches to dissect-
ing out LKB1/AMPK function. However, these strategies will be
most valuable by generating testable models that will ultimately
rely on a combination of approaches ranging from complex cell
biological analysis to metabolomic studies in trying to establish
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